Background More than half of patients with polymyalgia rheumatica have a relapse during tapering of glucocorticoid therapy. Previous studies have suggested that interleukin-6 blockade may be ...

Please provide your email address to receive an email when new articles are posted on . Patients were more likely to achieve sustained remission with sarilumab vs. placebo. The most common adverse ...

Credit: Shutterstock. Patients in the sarilumab vs placebo group achieved sustained remission of polymyalgia rheumatica at higher rates. Sarilumab demonstrates significant efficacy and is safe in the ...

Patients should be monitored for evidence of relapse, for disease-related complications, for steroid-related complications and for symptoms that may suggest an alternative diagnosis. In addition to ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Clinicians and ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. So this is a work in progress and we need ...